Aurobindo Pharma USA Inc. is recalling 88,600 vials of Lidocaine HCl Injection, USP 1% 50 mg/5 mL (10 mg/mL). The recall was initiated because a single vial was found to contain a human hair, which is considered particulate matter contamination. This prescription medication is an injectable local anesthetic and was manufactured in India for AuroMedics Pharma LLC.
Injecting a product containing particulate matter, such as a hair, can cause local inflammation, granulomas, or more serious systemic issues like blood clots or organ damage if the particles travel through the bloodstream. While the product is currently being held at distributor sites and not further distributed in the U.S. market, any contamination in an injectable drug poses a critical safety risk.
Drug recall baseline remedy
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.